Section Arrow
IMMP.NASDAQ
- Immutep Limited
Quotes are at least 15-min delayed:2024/10/31 18:52 EDT
Last
 1.815
-0.135 (-6.92%)
Day High 
1.95 
Prev. Close
1.95 
1-M High
2.215 
Volume 
132.96K 
Bid
1.81
Ask
1.88
Day Low
1.8 
Open
1.92 
1-M Low
1.86 
Market Cap 
283.26M 
Currency USD 
P/E -- 
%Yield -- 
10-SMA 1.94 
20-SMA
50-SMA 2.24 
52-W High 3.335 
52-W Low 1.58 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-0.39/-0.43
Enterprise Value
284.30M
Balance Sheet
Book Value Per Share
0.89
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
0
Operating Revenue Per Share
0.00
Industry Comparison
Code Name   Last Change Change (%) P/E P/E Range
ELABElevai Labs0.059-0.0339-36.49%-- 
AVTEAerovate Therapeutics2.46+0.27+12.33%-- 
ENSCEnsysce Biosciences0.5754-0.0629-9.85%-- 
TNXPTonix Pharmaceuticals Holding Corp.0.1445-0.0099-6.41%-- 
GLYCGlycoMimetics0.4069-0.0496-10.87%-- 
Quotes are at least 15-min delayed:2024/10/31 18:52 EDT
Industry overview quotes are at least 15 minutes delayed
Business Description
Immutep Ltd is a globally active biotechnology company developing immunotherapy products for cancer and autoimmune diseases. Its main product is IMP321, which involves clinical development for the treatment of cancer indications. The company is also focused on the development of other products, which include IMP701, which is a blocking anti-LAG-3 antibody for cancer and is in Phase I of its clinical trials, and CVac, which is a personalized immunocellular therapeutic investigated for the treatment of epithelial cancer. Geographically all the business activity of the firm is functioned through the region of Australia.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.